Influence of high dose intraoperative remifentanil with or without amantadine on postoperative pain intensity and morphine consumption in major abdominal surgery patients

Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Campus Charite Mitte und Virchow Klinikum, Charite - Universitätsmedizin Berlin0 sites48 target enrollmentApril 30, 2013

ConditionsPostoperative pain intensity and morphine consumption after elective lower abdominal surergy

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Postoperative pain intensity and morphine consumption after elective lower abdominal surergy
Sponsor: Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Campus Charite Mitte und Virchow Klinikum, Charite - Universitätsmedizin Berlin
Enrollment: 48
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

April 30, 2013

End Date

April 30, 2007

Last Updated

last year

Study Type

Interventional

Sex

All

Investigators

Sponsor

Klinik für Anästhesiologie mit Schwerpunkt operative Intensivmedizin, Campus Charite Mitte und Virchow Klinikum, Charite - Universitätsmedizin Berlin

Eligibility Criteria

Inclusion Criteria

•1\) patients of at least 18 years; 2\) American Society of Anaesthesiologists physical Status I – II; 3\) open surgical procedures of the lower abdomen \[(hemi\-)colectomy, anterior rectum resection; abdominoperineal rectum resection; radical prostatectomy (RPX)] with an anticipated duration of anaesthesia of at least 90 minutes

Exclusion Criteria

•(1\) were operated by laparoscopy; (2\) had to be transfused with \= 2 units of packed red blood cells; (3\) could not be extubated immediately after surgery; (4\) had a chronic inflammatory disease, including inflammatory bowel disease; (5\) had acute infection and/or SIRS/Sepsis; (6\) had used opioids within 12 h before surgery4; (7\) had a history of drug or alcohol abuse, psychiatric disorders or obesity (BMI \> 30 kg/m2\); (8\) had contraindications to the self\-administration of opioids (i.e., patients were unable to understand the patient\-controlled intravenous analgesia \[PCIA] device or had obstructive sleep apnea syndrome); (9\) had contraindications to the use of amantadine (e.g., heart rhythm or conductance disturbance, renal insufficiency, epilepsy, delirium)